



## **Viridian Therapeutics to Present Preclinical Data on VRDN-001 and VRDN-002 at the 90th Annual Meeting of the American Thyroid Association**

September 30, 2021

WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies, announced today that two posters featuring preclinical data on VRDN-001 and VRDN-002 are scheduled to be presented at the 90th Annual Meeting of the American Thyroid Association (ATA), which is being held from September 30<sup>th</sup> through October 3<sup>rd</sup>.

### Poster Presentation Details:

**Title:** VRDN-002, A Second-Generation Insulin Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody for Thyroid Eye Disease: Preclinical Pharmacokinetic Profile and Clinical Promise  
**Poster:** #37  
**Poster Session (1):** Thursday Poster Review Session  
**Time and Date:** Thursday, September 30, 2021, 12:15-1:00 p.m. EDT (Virtual Poster)  
**Poster Session (2):** Thursday Highlighted Posters Session #3  
**Time and Date:** Thursday, September 30, 2021, 4:00-5:00 p.m. EDT

**Title:** Characterization of VRDN-001, a High Affinity and Potent anti-IGF-1R Inhibitory Antibody in Development for the Treatment of Thyroid Eye Disease  
**Poster #:** #187  
**Poster Session:** Saturday Poster Review Session  
**Time and Date:** Saturday, October 2, 2021, 1:00-2:00 p.m. EDT

### **About Viridian Therapeutics, Inc.**

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies. Viridian's most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED), a debilitating auto-immune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids. Viridian is based in Waltham, Massachusetts.

### **Viridian Contacts:**

**Investors:**  
Dan Ferry  
LifeSci Advisors  
617-430-7576  
[IR@viridiantherapeutics.com](mailto:IR@viridiantherapeutics.com)

**Media:**  
Darby Pearson  
Verge Scientific Communications  
703-587-0831  
[PR@viridiantherapeutics.com](mailto:PR@viridiantherapeutics.com)

Source: Viridian Therapeutics, Inc.